Search Result

Results for "

PC9

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (3) Autophagy (1) Btk (1) CDK (1) EGFR (6) Histone Demethylase (1) Itk (1) JAK (1) JNK (1) NF-κB (1) Nucleoside Antimetabolite/Analog (1) p38 MAPK (1) PD-1/PD-L1 (1) Phosphatase (1) PI3K (1) PI4K (1) Polo-like Kinase (PLK) (1) PROTACs (2) Raf (1) SHP2 (1) Src (1) STAT (1)
By Research Areas:	Cancer (18)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150023

BI-1622	EGFR Itk PI4K Btk CDK Raf JAK	Cancer
BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC₅₀ of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile .

HY-139781

PD-L1-IN-1	PD-1/PD-L1	Cancer
PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC₅₀ of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly increased interferon γ release and apoptotic induction of cancer cells, with low cytotoxicity in healthy cells .

HY-B0021S

Doxifluridine-d2 Ro 21-9738-d₂; 5-Fluoro-5'-deoxyuridine-d₂; 5'-DFUR-d₂	Nucleoside Antimetabolite/Analog	Cancer
Doxifluridine-d₂ is the deuterium labeled Doxifluridine[1]. Doxifluridine is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 μM.

HY-157564

Antitumor agent-135	Apoptosis	Cancer
Antitumor agent-135 (Compound 13) is a potent antitumor agent. Antitumor agent-135 induces cell apoptosis, with IC₅₀s of 3.79 , 10.55, 1.14, and 4.14 μM for NSCLC cell lines (A549, H460, PC-9, and PC-9/GR) .

HY-157413

YS-67	EGFR	Cancer
YS-67 is a potent inhibitor of EGFR with an IC ₅₀ of 5.2 nM. YS-67 significantly inhibits p-EGFR and p-AKT. YS-67 inhibits the proliferation of A549, PC-9, and A431cells with IC ₅₀s of 4.1, 0.5, and 2.1 μM, respectively .

HY-153901

PROTAC EGFR degrader 8	EGFR PROTACs	Cancer
PROTAC EGFR degrader 8 (T-184) is a PROTAC EGFR degrader. PROTAC EGFR degrader 8 degrades EGFR in HCC827 cell with a DC₅₀ of 15.56 nM. PROTAC EGFR degrader 8 inhibits H1975, PC-9, HCC827 cell growth with IC₅₀s of 7.72 nM, 121.9 nM, 14.21 nM. PROTAC EGFR degrader 8 can be used for research of cancer, especially NSCLC .

HY-155227B

ALK/EGFR-IN-3	Anaplastic lymphoma kinase (ALK)	Cancer
ALK/EGFR-IN-3 is a dual inhibitor of ALK and EGFR. ALK/EGFR-IN-3 inhibits the cell proliferation of H1975, PC9, and Baf3-EML4-ALK cancer cell lines with IC₅₀s of 0.1360, 0.0332, and 0.0339 μM, respectively .

HY-108016

Peruvoside Encordin	Src PI3K JNK STAT EGFR Apoptosis Autophagy	Cancer
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib .

HY-147682

NF-κB-IN-5	NF-κB Apoptosis	Cancer
NF-κB-IN-5 (compound 4d) is an orally active and potent NF-κB inhibitor by interacting directly with NF-κB. NF-κB-IN-5 shows antitumor activity against human cancer cell lines (HCT116, U87-MG, HepG2, BGC823, PC9), with IC₅₀ values of 5.35, 2.81, 2.83, 2.02 and 3.90 μM, respectively. NF-κB-IN-5 induces apoptosis in U87-MG tumor cell and cell cycle arrest in G0/G1 phase .

HY-155227A

ALK/EGFR-IN-2	Anaplastic lymphoma kinase (ALK)	Cancer
ALK/EGFR-IN-2 is a potent dual inhibitor of ALK and EGFR. ALK/EGFR-IN-2 induces apoptosis and G0/G1 cell cycle arrest in cancer cells. ALK/EGFR-IN-2 significantly inhibits the cell proliferation of H1975, PC9, and Baf3-EML4-ALK cancer cell lines with IC₅₀s of 0.0034, 0.0065, and 0.0018 μM, respectively .

HY-143445

EGFR-IN-48	EGFR	Cancer
EGFR-IN-48 is a potent and orally active EGFR inhibitor with IC₅₀s of 0.193 nM, 0.251 nM, 10.4 nM for EGFR ^d19/TM/CS, EGFR ^LR/TM/CS, EGFR ^WT, respectively. EGFR-IN-48 inhibits the proliferation of BaF3 ^{EGFR del19/T790M/C797S} and PC-9 ^{EGFR del19/T790M/C797S} cells with IC₅₀s of 1.526, 66.7 nM, respectively .

HY-100014

KDM5A-IN-1 2 Publications Verification	Histone Demethylase	Cancer
KDM5A-IN-1 is a potent, orally bioavailable pan-histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC₅₀ value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other KDM5B enzymes (1A, 2B, 3B, 4C, 6A, 7B) .

HY-17602

Amcasertib BBI503	Others	Cancer
Amcasertib (BBI503) is an orally active and small-molecule multi-kinase inhibitor. Amcasertib exhibits inhibitory activity against the NANOG and CD133 expression and cell viability in PC-9/GR cells. As an orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity, it is currently being studied in phase I clinical trials in a number of cancers.

HY-142678

EGFR-IN-21

EGFR Cancer

EGFR-IN-21 is a potent EGFR inhibtior with an IC₅₀ of 0.38 nM. EGFR-IN-21 has antitumor activity .
HY-141524

RMC-3943

SHP2 Phosphatase Cancer

RMC-3943 is an allosteric SHP2 inhibitor (inhibition of full-length SHP2 in biochemical assay, IC₅₀ = 2.19 nM) .

EGFR-IN-21	EGFR	Cancer
EGFR-IN-21 is a potent EGFR inhibtior with an IC₅₀ of 0.38 nM. EGFR-IN-21 has antitumor activity .

RMC-3943	SHP2 Phosphatase	Cancer
RMC-3943 is an allosteric SHP2 inhibitor (inhibition of full-length SHP2 in biochemical assay, IC₅₀ = 2.19 nM) .

HY-157427

PROTAC PLK1 Degrader-1	PROTACs Polo-like Kinase (PLK)	Cancer
PROTAC PLK1 Degrader-1 (DD-2) is a potent PROTAC PLK1 degrader. PROTAC PLK1 Degrader-1 selectively induces PLK1 degradation in cancer cells, including HeLa (DC₅₀=2.5 μM) and nonsmall cell lung cancer (NSCLC), through the N-degron pathway .

HY-151606

Akt3 degrader 1	Akt	Cancer
Akt3 degrader 1 (compound 12l) is a selective Akt3 degrader that overcomes Osimertinib (HY-15772)-induced resistance in H1975OR NSCLC cells. Akt3 degrader 1 also has anti-proliferative activity and significantly inhibits tumour growth in mice. Akt3 degrader 1 can be used in the study of drug-resistant non-small cell lung cancer .

HY-122872

MKK7-COV-9	p38 MAPK	Cancer
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC₅₀ of 4.98 μM .

Peruvoside Encordin	Apocynaceae Triterpenes Structural Classification Terpenoids Source classification Thevetia peruviana (Pers.) K. Schum. Plants	Src PI3K JNK STAT EGFR Apoptosis Autophagy
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib .

Species:	Human (7) Rhesus Macaque (1) Mouse (3) Rat (1) Cynomolgus (1)
Tag:	His (11) Avi (3) HA (1) Fc (1)
Source:	HEK293 (13)

Cat. No.	Compare	Product Name	Species	Source

HY-P78824

	PCSK9 Protein, Human (Biotinylated, HEK293, D374Y, His-Avi) PCSK9; FH3; HCHOLA3; LDLCQ1; NARC1; PC9	Human	HEK293
	PCSK9 protein, a crucial regulator of plasma cholesterol homeostasis, influences LDL receptor family members like LDLR and VLDLR. It facilitates their degradation within intracellular compartments, enhancing hepatic LDLR degradation through a non-proteolytic mechanism. PCSK9 also exhibits LDLR-independent inhibition of APOB degradation and regulates ENaC-mediated Na(+) absorption, influencing neuronal apoptosis. Notably, it modulates LRP8/APOER2 levels and associated anti-apoptotic pathways. PCSK9 Protein, Human (Biotinylated, HEK293, D374Y, His-Avi) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-Avi, C-His labeled tag and D374Y mutation. The total length of PCSK9 Protein, Human (Biotinylated, HEK293, D374Y, His-Avi) is 662 a.a., with molecular weight of 16 & 66 kDa, respectively.

HY-P78663

	PCSK9 Protein, Human (D374Y, HEK293, His) PCSK9; FH3; HCHOLA3; LDLCQ1; NARC1; PC9	Human	HEK293
	PCSK9 protein, a crucial regulator of plasma cholesterol homeostasis, influences LDL receptor family members like LDLR and VLDLR. It facilitates their degradation within intracellular compartments, enhancing hepatic LDLR degradation through a non-proteolytic mechanism. PCSK9 also exhibits LDLR-independent inhibition of APOB degradation and regulates ENaC-mediated Na(+) absorption, influencing neuronal apoptosis. Notably, it modulates LRP8/APOER2 levels and associated anti-apoptotic pathways. PCSK9 Protein, Human (D374Y, HEK293, His) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-10*His labeled tag and D374Y mutation. The total length of PCSK9 Protein, Human (D374Y, HEK293, His) is 662 a.a., with molecular weight of ~17 & 70 kDa, respectively.

HY-P70545A

	PCSK9 Protein, Human (HEK293, C-His) 1 Publications Verification Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (HEK293, C-His) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PCSK9 Protein, Human (HEK293, C-His) is 662 a.a., with molecular weight of approximately 20.33 & 59 kDa, respectively.

HY-P72405

	PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, Avi) Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9	Human	HEK293
	PCSK9 protein, a crucial regulator of plasma cholesterol homeostasis, influences LDL receptor family members like LDLR and VLDLR. It facilitates their degradation within intracellular compartments, enhancing hepatic LDLR degradation through a non-proteolytic mechanism. PCSK9 also exhibits LDLR-independent inhibition of APOB degradation and regulates ENaC-mediated Na(+) absorption, influencing neuronal apoptosis. Notably, it modulates LRP8/APOER2 levels and associated anti-apoptotic pathways. PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, Avi) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-Avi labeled tag and V474I, G670E mutation. The total length of PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, Avi) is 662 a.a., with molecular weight of 19 & 65 kDa, respectively.

HY-P71189A

	PCSK9 Protein, Mouse (HEK293, His) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCsk9; Narc1	Mouse	HEK293
	The PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 receptors. It promotes LDLR degradation, inhibits recycling, induces ubiquitination, and affects APOB degradation. Additionally, PCSK9 influences BACE1 intermediates, ENaC surface expression, and neuronal apoptosis by modulating LRP8/APOER2 levels and anti-apoptotic signaling pathways. PCSK9 Protein, Mouse (HEK293, His) is a recombinant protein dimer complex containing mouse-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag. PCSK9 Protein, Mouse (HEK293, His), has molecular weight of 19.37 & 55 kDa, respectively.

HY-P73339

	PCSK9 Protein, Mouse (660a.a, HEK293, His) Proprotein convertase subtilisin/kexin type 9; NARC-1; PC9; PCSK9	Mouse	HEK293
	The PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 receptors. It promotes LDLR degradation, inhibits recycling, induces ubiquitination, and affects APOB degradation. Additionally, PCSK9 influences BACE1 intermediates, ENaC surface expression, and neuronal apoptosis by modulating LRP8/APOER2 levels and anti-apoptotic signaling pathways. PCSK9 Protein, Mouse (660a.a, HEK293, His) is the recombinant mouse-derived PCSK9 protein, expressed by HEK293 , with C-His labeled tag. The total length of PCSK9 Protein, Mouse (660a.a, HEK293, His) is 660 a.a., with molecular weight of ~19 & 65 kDa, respectively.

HY-P75958

	PCSK9 Protein, Rhesus Macaque (HEK293, His) Proprotein convertase subtilisin/kexin type 9; NARC-1; PC9; PCSK9	Rhesus Macaque	HEK293
	PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER and LRP8/APOER2 receptors. It promotes LDLR degradation through non-proteolytic mechanisms, disrupts LDLR recycling, induces LDLR ubiquitination, and inhibits APOB degradation. PCSK9 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived PCSK9 protein, expressed by HEK293 , with C-His labeled tag. The total length of PCSK9 Protein, Rhesus Macaque (HEK293, His) is 662 a.a., with molecular weight of ~20 & 62 kDa, respectively.

HY-P73728

	PCSK9 Protein, Human (HEK293, Fc) Proprotein convertase subtilisin/kexin type 9; NARC-1; PC9; PCSK9	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (HEK293, Fc) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-mFc labeled tag. The total length of PCSK9 Protein, Human (HEK293, Fc) is 662 a.a., with molecular weight of ~97.4 kDa.

HY-P73340

	PCSK9 Protein, Rat (HEK293, His) 1 Publications Verification Proprotein convertase subtilisin/kexin type 9; NARC-1; PC9; PCSK9	Rat	HEK293
	The PCSK9 protein regulates cholesterol levels by interacting with LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2. It promotes their degradation and inhibits their recycling, leading to enhanced LDLR degradation. PCSK9 also affects APOB degradation, BACE1 intermediates, ENaC surface expression, and neuronal apoptosis via LRP8/APOER2. PCSK9 Protein, Rat (HEK293, His) is the recombinant rat-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PCSK9 Protein, Rat (HEK293, His) is 661 a.a., with molecular weight of ~17.26 & 60.16 kDa, respectively.

HY-P70546

	PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, His-HA-Avi) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, His-HA-Avi) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-Avi, C-HA, C-8*His labeled tag and V474I, G670E, , , mutation. The total length of PCSK9 Protein, Human (Biotinylated, V474I, G670E, HEK293, His-HA-Avi) is 662 a.a., with molecular weight of 18 & 58-70 & 90-150 kDa, respectively.

HY-P70545

	PCSK9 Protein, Human (HEK293, V474I, G670E, His) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1	Human	HEK293
	The PCSK9 protein is an important regulator of plasma cholesterol homeostasis, affecting LDL receptor family members such as LDLR and VLDLR. It promotes their intracellular degradation and enhances hepatic LDLR degradation through non-proteolytic mechanisms. PCSK9 Protein, Human (HEK293, V474I, G670E, His) is the recombinant human-derived PCSK9 protein, expressed by HEK293 , with C-6*His labeled tag and V474I, G670E, , , mutation. The total length of PCSK9 Protein, Human (HEK293, V474I, G670E, His) is 662 a.a., with molecular weight of 19 & 60 kDa, respectively.

HY-P71189

	PCSK9 Protein, Mouse (HEK293, His, solution) Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCsk9; Narc1	Mouse	HEK293
	The PCSK9 protein regulates cholesterol levels by degrading LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 receptors. It promotes LDLR degradation, inhibits recycling, induces ubiquitination, and affects APOB degradation. Additionally, PCSK9 influences BACE1 intermediates, ENaC surface expression, and neuronal apoptosis by modulating LRP8/APOER2 levels and anti-apoptotic signaling pathways. PCSK9 Protein, Mouse (HEK293, His, solution) is a recombinant protein dimer complex containing mouse-derived PCSK9 protein, expressed by HEK293, with C-6*His labeled tag. PCSK9 Protein, Mouse (HEK293, His, solution), has molecular weight of 17-19 & 60-66 kDa, respectively.

HY-P70966

	PCSK9 Protein, Macaca nemestrina (HEK293, His) Proprotein Convertase Subtilisin/Kexin Type 9; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9	Cynomolgus	HEK293
	The PCSK9 protein controls plasma cholesterol levels by interacting with LDLR, VLDLR, LRP1/APOER, and LRP8/APOER2 to promote their degradation. It prevents LDLR recycling and directs it to lysosomes for degradation. PCSK9 induces LDLR ubiquitination, inhibits APOB degradation, disposes of BACE1 intermediates, reduces ENaC surface expression, and regulates neuronal apoptosis through LRP8/APOER2. PCSK9 Protein, Macaca nemestrina (HEK293, His) is a recombinant protein dimer complex containing cynomolgus-derived PCSK9 protein, expressed by HEK293, with C-6*His labeled tag. PCSK9 Protein, Macaca nemestrina (HEK293, His), has molecular weight of (16-21) & (55-77) kDa, respectively.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Doxifluridine-d2
Doxifluridine-d₂ is the deuterium labeled Doxifluridine[1]. Doxifluridine is a thymidine phosphorylase activator for PC9-DPE2 cells with IC50 of 0.62 μM.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PC9

Inhibitors & Agonists

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products